Gilead Sciences operates as a global biopharmaceutical company focused on antiviral therapies. Leaders, boards, and regulators define how the company runs day to day research, manufacturing, and patient programs.
The organization balances scientific innovation with commercial obligations, shaping how treatments reach people around the world. Below is a structured overview of who runs Gilead and how key functions are organized.
| Role | Name | Key Responsibility | Primary Oversight Area |
|---|---|---|---|
| Chief Executive Officer | Daniel B. O'Day | Global strategy, major partnerships, financial performance | Executive leadership and board alignment |
| Chief Scientific Officer | Johanna T. Neumann | Pipeline oversight, translational research, regulatory pathways | R&D strategy and clinical development |
| Chief Medical Officer | Merdad Parsey | Clinical trial design, safety, and medical affairs | Study execution and therapeutic outcomes |
| Chief Financial Officer | John F. Milligan | Finance, treasury, pricing, and investor relations | Budgeting, forecasting, and compliance |
| Chief Corporate Affairs Officer | Rob Phillips | Policy engagement, public strategy, corporate responsibility | Government, community, and ethical programs |
| General Counsel | Jonathan D. Roberts | Legal risk, compliance, intellectual property | Regulatory, litigation, and governance matters |
Executive Leadership and Corporate Governance
Day to day governance at Gilead rests with executive leadership teams and a publicly accountable board. The board sets oversight priorities, while senior function heads implement strategy across therapeutic areas and regions.
Corporate governance documents outline committee charters, independence criteria, and risk frameworks. These structures clarify who runs Gilead at the highest decision level, linking scientific and commercial choices to shareholder and public expectations.
Research and Development Organization
R&D leadership guides a portfolio spanning oncology, liver diseases, and inflammatory conditions. Decisions on which programs advance rely on cross functional review, external advisory input, and evolving regulatory expectations.
Scientists, clinicians, and operations professionals coordinate across discovery, preclinical, and clinical stages. This integrated model allows rapid pivots while maintaining rigorous safety and efficacy standards.
Commercial Operations and Global Health Partnerships
Commercial teams manage access, pricing strategies, and patient support programs in diverse markets. They balance revenue targets with equitable access initiatives, working alongside governments and payers.
Global health partnerships focus on disease elimination, affordability, and capacity building. These collaborations reshape how therapies are delivered in low resource settings and influence long term sustainability.
Manufacturing, Supply Chain, and Compliance
Manufacturing leaders oversee facility standards, quality control, and technology upgrades that ensure reliable drug supply. Site selection and capacity planning reflect both strategic and regulatory considerations.
Supply chain teams coordinate sourcing, logistics, and cold chain requirements across continents. Compliance units monitor evolving laws, anti corruption measures, and environmental practices across operations.
Corporate Direction and Future Focus
As Gilead navigates evolving science and policy landscapes, leadership emphasizes disciplined innovation and responsible growth. Strategic clarity shapes how therapies move from research sites to patient communities.
- Define long term strategic pillars aligned with public health priorities
- Strengthen R&D pipelines through targeted partnerships and internal innovation
- Enhance access and affordability initiatives across global markets
- Maintain rigorous compliance, quality, and environmental standards
- Communicate progress transparently to investors, patients, and policymakers
FAQ
Reader questions
How does Gilead set pricing for its antiviral and oncology drugs in different countries?
Pricing decisions consider market specific factors such as payer formularies, budget impact analyses, and access agreements. Teams collaborate with health authorities to align launch strategies with local value assessments and reimbursement timelines.
Who decides which disease areas Gilead prioritizes for new research programs? What role do patients and advocacy groups play in guiding Gilead's clinical trial designs?
Patient insights help refine eligibility criteria, endpoints, and trial protocols to improve feasibility and relevance. Engagement continues through patient advocacy alliances and community feedback mechanisms.
How transparent is Gilead about its financial performance and future guidance?
Investor relations provide quarterly and annual reports, conference calls, and updated guidance documents. Leadership explains key drivers, risks, and strategic milestones to maintain clarity for stakeholders.